This article is more than 5 years old. Information may no longer be current.

Aesculap announces first human implantation of Novocart 3-D

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aesculap Biologics recently announced that the first clinical study patient was implanted with the company’s Novocart 3-D product.

Part of a U.S. Food and Drug Administration Investigational New Drug phase 3, randomized, partially blinded, multicenter study, the matrix-induced, autologous chondrocyte product is designed to repair articular cartilage defects of the knee, according to a company press release.

The product places healthy cartilage cells harvested from the patient on a collagen-based scaffold; after a 21- to 25-day growth period, the final scaffold is implanted into the patient’s defective knee cartilage to help relieve pain and restore normal function, according to the release.